文献速递临床微生物分子诊断质量管理与危急值

Abbott BinaxNOW SARS-CoV-2抗原检测在社区检测点与rRT-PCR及病毒培养的性能比较

Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020.
PubMed 文献 · J Clin Microbiol · 2021-10-27

BinaxNOW总体灵敏度52.5%,有症状且已知暴露者灵敏度65.7%,症状出现一周内71.1%,暴露后8-10天75%。BinaxNOW阳性标本病毒培养阳性预测值56.7%,rRT-PCR阳性为35.4%;报告时间分别为2.5小时和26小时。

要点

  • BinaxNOW抗原检测总体灵敏度52.5%,有症状且已知暴露者升至65.7%。
  • 症状出现一周内灵敏度71.1%,暴露后8-10天灵敏度最高75%。
  • BinaxNOW阳性标本病毒培养阳性预测值56.7%,高于rRT-PCR阳性的35.4%。

核心结论

  • BinaxNOW抗原检测灵敏度低于rRT-PCR,但在有症状且已知暴露者中灵敏度提高。
  • 抗原检测报告时间2.5小时,短于rRT-PCR的26小时,有助于快速识别感染者。
  • 制定检测程序时需考虑抗原检测灵敏度的局限性。

研究设计与样本

  • 同时进行rRT-PCR和Abbott BinaxNOW抗原检测,任一检测阳性的标本进行病毒培养。
  • 通过问卷收集症状、已知暴露状态和既往SARS-CoV-2检测结果。

主要发现

  • BinaxNOW总体灵敏度为52.5%。
  • 有症状且报告已知暴露的个体灵敏度为65.7%。
  • 已知暴露且既往有症状者灵敏度32.4%,从未有症状者47.1%。
  • 症状出现一周内灵敏度71.1%,已知暴露者暴露后8-10天灵敏度75%。
  • BinaxNOW阳性标本病毒培养阳性预测值56.7%,rRT-PCR阳性标本为35.4%。

关键数值与推荐

  • BinaxNOW报告时间2.5小时,rRT-PCR报告时间26小时。

临床怎么用

  • 抗原检测 turnaround time 短于实验室核酸检测,可更快速识别感染者。
  • 制定检测程序时应考虑抗原检测灵敏度的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott BinaxNOW antigen test at two community testing sites in Pima County, Arizona. We administered a questionnaire to capture symptoms, known exposure status, and previous SARS-CoV-2 test results. Specimens positive by either test were analyzed by viral culture. Previously we showed overall BinaxNOW sensitivity was 52.5%. Here, we showed BinaxNOW sensitivity increased to 65.7% among currently symptomatic individuals reporting a known exposure. BinaxNOW sensitivity was lower among participants with a known exposure and previously symptomatic (32.4%) or never symptomatic (47.1%) within 14 days of testing. Sensitivity was 71.1% in participants within a week of symptom onset. In participants with a known exposure, sensitivity was highest 8 to 10 days postexposure (75%). The positive predictive value for recovery of virus in cell culture was 56.7% for BinaxNOW-positive and 35.4% for rRT-PCR-positive specimens. Result reporting time was 2.5 h for BinaxNOW and 26 h for rRT-PCR. Point-of-care antigen tests have a shorter turnaround time than laboratory-based nucleic acid amplification tests, which allows for more rapid identification of infected individuals. Antigen test sensitivity limitations are important to consider when developing a testing program.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Almendares O, Prince-Guerra JL, Nolen LD, et al. Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020. J Clin Microbiol. 2021. PMID: 34705535. doi:10.1128/JCM.01742-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。